Skyhawk Therapeutics veröffentlicht die Ergebnisse der cUHDRS-Unterkomponenten nach zwölf Monaten aus seiner klinischen Phase-1/2-Studie mit SKY-0515 bei der Huntington-Krankheit

Skyhawk Therapeutics präsentiert 12‑Monatsdaten zu SKY-0515: beim TFC zeigte sich eine durchschnittliche Verbesserung von +0,07 vs erwartete Verschlechterung von -0,87; beim TMS von -2,00 vs erwartete +2,21; zudem günstige Stabilisierung bei SDMT (-0,19 vs erwartete -1,78) und Verbesserung bei SWRT (+3,44 vs erwartete -3,13). In der Studie wurden außerdem dosisabhängig mHTT im Blut um bis zu 69% und PMS1‑mRNA um bis zu 26% reduziert sowie in CGI/PGI nach 12 Monaten keine Verschlechterung berichtet (65% der Teilnehmer und 50% der Ärzte meldeten Besserung). Das Sicherheitsprofil wird als allgemein sicher und gut verträglich beschrieben; das Programm umfasst >175 Teilnehmer aus fünf Ländern.

Analysis

This is more important as a modality signal than a single-asset print. A credibly oral, CNS-penetrant approach that appears to hit both huntingtin and a somatic-expansion target would shift investor preference toward chronic, low-friction therapies and away from intrathecal or one-shot strategies that must now prove superiority on convenience, tolerability, and durability rather than biomarker movement alone.

The near-term winner set is likely broader RNA/CNS platform names with diversified pipelines, while the most exposed losers are HD programs that still require repeated lumbar punctures and/or have weaker translational visibility. In practice, that means relative pressure on WVE and any late-stage ASO read-through, with QURE less directly threatened but still facing a higher bar if a daily pill can achieve meaningful functional preservation. The second-order effect is that capital may rotate back into rare-neuro exploration, but only for platforms that can show clean randomized clinical separation.

The market is most likely to overread the extension data and underweight how noisy global impression scores are in small, open-label cohorts. The real catalyst is the placebo-adjusted FALCON-HD readout over the next 1-3 months; if the clinical delta collapses while biomarkers remain strong, the story reverts to "interesting biology" rather than a de-risked franchise. Conversely, persistent functional separation would force a repricing of the entire HD competitive set over 6-18 months as commercial models move from niche infusion economics to chronic oral adherence economics.

Key Decisions for Investors

• Relative-value short WVE / long IONS into the next 1-3 month HD catalyst window; WVE is more exposed to a credible oral CNS competitor, while IONS can capture broad RNA-validation upside with lower single-asset risk.
• Avoid chasing QURE on this headline alone; if anything, use strength to trim, since a daily oral disease-modifying alternative would compress the long-term TAM for one-time HD gene therapy unless its durability data materially improves.
• Set a watch alert on FALCON-HD placebo-adjusted cUHDRS and mHTT separation; only add risk if the randomized readout shows durable clinical separation, not just biomarker suppression.
• For broader exposure, bias toward diversified CNS/rare-disease biotech baskets over single-asset HD names; if the thesis is real, multiple platform names should rerate before commercialization risk clears.